Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a clinical-stage biopharmaceutical company operating in the biotechnology sector that entered public markets through a SPAC business combination. The company filed a Form 10-K/A — an amendment to its annual report — with the Securities and Exchange Commission on April 1, 2024, under accession number 0001193125-24-082201, reflecting updated disclosures for the reporting period. Abpro focuses on developing next-generation antibody-based therapeutics targeting oncology and other serious diseases, and the amended filing represents the company's continued post-merger reporting obligations as a de-SPAC public entity. Investors and analysts seeking full filing history, sponsor details, and real-time analytics on Abpro Holdings and the broader SPAC universe can sign up for complete data at SpacDesk.